Knowledge Library

Engineered cell line panel complemented with in vivo models to enable next-generation target therapy discovery in cancer

 AACR Annual meeting 2021   Authors: Zhixiang Zhang1, Feifei Fan2, Xiaohe Shi2, Xiangyang Zuo2, Qingyang Gu2, Qunsheng Ji1. 1 WuXi AppTec, Shanghai, China; 2 WuXi AppTec, Jiangsu, China Corresponding Author: Qunsheng Ji. Email: ji_qunsheng@wuxiapptec.com   Background  Many cancer types are driven by specific gene aberrances, like gene fusions, mutations and copy number changes. It has led to …Read More >

Resource Type: Poster
Resource Topic: Biomarkers Cell-based Assays Oncology Phenotypic Assays Target Identification and Validation Tumor Models

VIEW

Drug Hunter: Discovering New Frontiers in Cancer Treatments & Beyond

INNOVATION THAT MATTERS By Rich Soll, Senior Advisor, Strategic Initiatives at WuXi AppTec (@richsollwx) As a self-proclaimed drug hunter, Phil Jones is on a mission to identify the next generation of cancer medicines that improve the lives of patients with cancer. He leads a multi-disciplinary team of scientists at The University of Texas MD Anderson Cancer Center’s Institute …Read More >

Resource Type: Article
Resource Topic: Biomarkers CAR-T Cell Cells and Protein Science Chemical Biology and Proteomics DRUG DISCOVERY AND INNOVATION Hit Finding in vitro biology in vivo Pharmacology Oncology Phenotypic Assays Small Molecules Target Identification and Validation

VIEW

Establishment of KRAS-G12C inhibitor induced resistant tumor models enable the development of new generation KRAS-G12C inhibitors and combinatorial strategies

Activating KRAS mutations, including G12C and G12D, are detected in approximately 25% of human cancers. The most common KRAS mutation is G12C, which comprises nearly 15% of lung adenocarcinomas, 8% of colorectal carcinomas and 4% of pancreatic adenocarcinomas. AMG-510 from Amgen and MRTX849 from Mirati Therapeutics, both targeting the KRASG12C mutant, have shown encouraging results …Read More >

Resource Type: Poster
Resource Topic: Biochemical Assays Oncology Phenotypic Assays Small Molecules Target Identification and Validation Tumor Models

VIEW

Translational Oncology

Biomarker discovery Mouse clinical trial 61 PDX-derived primary cancer cell lines Drug-resistant xenograft models Combination therapy platform including radiation World leading genome sequencing and bioinformatics capability

Resource Type: Brochure
Resource Topic: Biomarkers Candidate Selection Cell-based Assays Cells and Protein Science Chemical Biology and Proteomics Lead Optimization Oncology Phenotypic Assays Tumor Models

VIEW

Immuno-Oncology Services

Immuno-oncology Platform An outstanding platform to enable cancer immunotherapy with one stop service: Immunological function assessment TIL analysis – Flowcytometry, Multiplex IF and Cytex Animal models – Syngeneic and humanized models Immune profiling by NGS – Single Cell RNAseq, Mutation burden and TCR/BCR repertoire Clinical biomarker services – CAP certification and GCP compliance

Resource Type: Brochure
Resource Topic: Antibodies Autoimmune and Inflammatory Diseases Biomarkers Cell-based Assays Cells and Protein Science Hit-to-Lead Immunology in vivo Pharmacology Lead Optimization Oncology Phenotypic Assays Target Identification and Validation Target-Specific Assays Tumor Models

VIEW

Virology and Viral Vector Platforms

WuXi virology platforms: Immunology, Anti viral, Viral Vector, Oligo-nucleotide, Clinical and Immunology in vitro screening and profiling in vivo efficacy clinical virology Liver-specific viruses | Respiratory viruses | Herpes viruses | Other viruses

Resource Type: Brochure
Resource Topic: Biochemical Assays Biomarkers Candidate Selection CAR-T Cell Cell-based Assays Cells and Protein Science in vivo Pharmacology in vivo Toxicology Infectious Diseases Lead Optimization Oncolytic Viruses Phenotypic Assays Safety and Early Toxicity

VIEW

Clinical Virology

Clinical Virology and Advanced Therapy Platforms Research Services: CAP Accredited Molecular Testing Laboratory Genetics and Biomarker Platform HBV Genotyping Assays HBV Serology Assays HBV Phenotyping Assays Immunological Assays Other Assays:  Oncolytic |  CAR-T/TCR-T Particular Solutions Clinical virology: Viral load, sequencing, genotyping, TCID50, phenotyping, virus isolation and characterization, serology Vaccines: Advanced therapies (Viral vector and cell therapies): …Read More >

Resource Type: Brochure
Resource Topic: Biomarkers Candidate Selection Cell Therapies Cells and Protein Science Infectious Diseases Oncolytic Viruses Phenotypic Assays Target-Specific Assays

VIEW

Establishment and Optimization of scRNA-seq assay to find the mechanism of immune therapy against tumors

Tumors are complex ecosystems composed of different cell types with different phenotypes, status and gene profiles. Commonly used GEP tools like bulk RNA Sequencing can only display gene expression profiles as a whole, and cannot reflect the heterogeneous tumor cell change or immune composition in a tumor. Single cell RNA sequencing is a good tool …Read More >

Resource Type: Poster
Resource Topic: Immunology Oncology Phenotypic Assays Target Identification and Validation

VIEW


Resource Topics
× peptide, amino acid

Contact An Expert Today!